- In the News
- Welcome to PDSA
Novartis Receives FDA Approval for Promacta as Treatment of Chronic ITP in Children
"Novartis announced that the US Food and Drug Administration (FDA) has approved Promacta (eltrombopag) for the treatment of children six years and older with chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Promacta was approved by the FDA in 2008 for use in adult patients with the same condition."
- From StreetInsider.com.
New Treatment Option for ITP in Development
"The US Food and Drug Administration (FDA) has accepted Protalex Inc.’s Investigational New Drug Application (IND) for PRTX-100, a highly purified form of Staphylococcal protein A, allowing clinical studies with the drug in patients with Immune Thrombocytopenia (ITP) to proceed."
- By Lorraine L. Janeczko, MPH for Rare Disease Report. Photo courtesy National Heart and Blood Institute.
Teen with rare blood disorder gets double treat: remission and graduation
"When 17 year-old Charity Lynn Anderson discovered she had a rare blood disease, she made it her goal to not just graduate high school on time but to also be in full remission when receiving her diploma."
- By Donna Cashen, Juneau Empire. Photo by Michael Penn, Juneau Empire.
"Making the world of ITP a more manageable place to be"
The Platelet Disorder Support Association is dedicated to enhancing the lives of people with immune thrombocytopenia (ITP) and other platelet disorders through:
Education • Advocacy • Research • Support
Comprehensive information on conventional therapies usually prescribed for ITP as well as therapies outside of the usual medical mainstream that some patients with ITP have used successfully.
Advocacy helps build awareness and support for ITP and other platelet disorders. Everyone interested in having more people know about ITP, having greater access to treatment, and getting more funding ITP and related diseases can help.
ITP Conference DVDs, free booklets and pamphlets, diet and lifestyle information, PDSA newsletters, journal articles and abstracts, PDSA E-News.